“Metabolic studies showed that diabetes increased plasma glucose and that alogliptin treatment reduced glucose.”
“Taken together, our findings showed that alogliptin-inhibited atherosclerosis in diabetic apolipoprotein E-deficient mice and that the actions of alogliptin on both glucose and inflammation may contribute to the inhibition.”